Encapsulation and controlled release of recombinant human erythropoietin from chitosan-carrageenan nanoparticles

Current Drug Delivery

Volumn 9, Issue 5, 2012, Pages 527-537

  Bulmer, Cody ^a   Margaritis, Argyrios ^a   Xenocostas, Anargyros ^b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b WESTERN UNIVERSITY   (Canada)

Author keywords

Carrageenan; Chitosan; Drug delivery; Erythropoietin; Nanoparticles; Response surface modeling

Indexed keywords

CARRAGEENAN; CHITOSAN; CHITOSAN CARRAGEENAN NANOPARTICLE; NANOPARTICLE; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED DRUG RELEASE; DISPERSION; DRUG DELIVERY SYSTEM; GELATION; IN VITRO STUDY; MOLECULAR WEIGHT; NANOENCAPSULATION; PARTICLE SIZE; PH; PRIORITY JOURNAL; RESPONSE SURFACE METHOD; SURFACE PROPERTY; SUSTAINED DRUG RELEASE;

CARRAGEENAN; CHITOSAN; DRUG CARRIERS; ERYTHROPOIETIN; MICROSCOPY, ELECTRON, TRANSMISSION; MODELS, CHEMICAL; NANOPARTICLES; PARTICLE SIZE; RECOMBINANT PROTEINS; SURFACE PROPERTIES;

EID: 84866982030     PISSN: 15672018     EISSN: 18755704     Source Type: Journal    
DOI: 10.2174/156720112802650680     Document Type: Article

References (46)

1. Lai, P.H.; Everett, R.; Wang, F.F.; Arakawa, T.; Goldwasser, E. Structural characterization of human erythropoietin. J. Biol. Chem., 1986, 261, 3116-3121.
2. nd ed.; John Wiley: USA, 2003.
3. Mocini, M.; Leone, T.; Tubaro, M.; Santini, M.; Penco, M. Structural, production and function of erythropoietin: implications for therapeutical use in cardiovascular disease. Curr. Med. Chem., 2007, 14, 2278-2287.
4. Jelkmann, W. Erythropoietin: structure, control of production, and function. Physiol. Rev., 1992, 72, 449-489.
5. Lacombe, C.; Mayeux, P. Biology of erythropoietin. Haematologica, 1998, 83, 724-32.
6. Wojchowski, D. Eugene Goldwasser (1922-2010). Nature, 2011, 470, 40.
7. Miyake, T.; Kung, C.K.H.; Goldwasser, E. Purification of human erythropoietin. J. Biol. Chem., 1977, 252, 5558-5564.
8. Eschbach, J.W.; Kelly, M.R.; Haley, N.R.; Abels, R.I.; Adamson, J.W. Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. N. Engl. Med., 1989, 321, 158-163.
9. Pistel, K.F.; Bittner, B.; Koll, H.; Winter, G.; Kissel, T. Biodegradable recombinant human erythropoietin loaded microspheres prepared from linear and star-branched block copolymers: influence of encapsulation technique and polymer composition on particle characteristics. J. Control. Release, 1999, 59, 309-325.
10. Lin, F.K.; Suggs, S.; Lin, C.H.; Browne, J.K.; Smalling, R.; Egrie, J.C.; Chen, K.K.; Fox, G.M.; Martin, F.; Stabinsky, Z.; Badrawi, S.M.; Lai, P.L.; Goldwasser, E. Cloning and expression of the human erythropoietin gene. Proc. Natl. Acad. Sci., 1985, 82, 7580-7584.
11. Broudy, V.C.; Tait, J.F.; Powell, J.S. Recombinant human erythropoietin: purification and analysis of carbohydrate linkage. Arch. Biochem. Biophys., 1988, 265, 329-336.
12. Vander, M.; Voors, A.A.; Lipsic, E.; Van Gilst, H.W.; Van Velduisen, D.J. Erythropoietin in cardiovascular diseases. Eur. Heart J., 2004, 25, 285-291.
13. Rui, T.; Fen, Q.; Lei, M.; Peng, T.; Zhang, J.; Xu, M.; Abel, E.D.; Xenocostas, A.; Kvietys, R.P. Erythropoietin prevents the acute myocardial inflammatory response induced by ischemia/ reperfusion via induction of AP-1. Cardiovas. Res., 2005, 65, 719-727.
14. Boogaerts, M. Pleiotropic effects of erythropoietin in neuronal and vascular systems. Curr. Med. Res. Opin., 2006, 22, 15-22.
15. Burger, D.; Lei, M.; Geoghegan-Morphet, N.; Lu, X.; Xenocostas, A.; Feng, Q. Erythropoietin protects cardiomyocytes from apoptosis via up-regulation of endothelial nitric oxide synthase. Cardiovas. Res., 2006, 72, 51-59.
16. Kao, R.; Xenocostas, A.; Rui, T.; Yu, P.; Huang, W.; Rose, J.; Martin, M.C. Erythropoietin improves skeletal muscle microcirculation and tissue bioenergetics in a mouse sepsis model. Crit. Care, 2007, 11, 58.
17. Arcasoy, M.O. The non-haematopoietic biological effects of erythropoietin. Br. J. Haematol., 2008, 141, 14-31.
18. Morlock, M.; Koll, H.; Winter, G.; Kissel, T. Microencapsulation of rh-Erythropoietin, using biodegradable poly (D.L-lactide-coglycolide): protein stability and the effects of stabilizing excipients. Eur. J. Pharm. Biopharm., 1997, 43, 29-36.
19. Hedley, B.D.; Allan, A.L.; Xenocostas, A. The role of erythropoietin and erythropoiesis-stimulating in tumor progression. Clin. Can. Res., 2011, 17, 6373-6380.
20. Kurita, K. Chitin and Chitosan: Functional biopolymers from marine crustaceans. Mar. Biotechnol., 2006, 8, 203-226.
21. Shanji, J.; Jain, V.; Lodha, S. Chitosan: a novel pharmaceutical excipient. Int. J. Pharm. App. Sci., 2010, 1, 11-28.
22. Hirano, S.; Seino, H.; Akiyama, Y.; Nonaka, I. Biocompatibility of chitosan by oral and intravenous administration. Polym. Eng. Sci., 1989, 59, 897-901.
23. Dornish, M.; Hagen, A.; Hansson, E.; Pecheur, C.; Verdier, F.; Skaugrad, O. Safety of protasan: ultrapure chitosan salts for biomedical and pharmaceutical use. Adva. Chitin Sci., 1997, 2, 664-670.
24. Lehr, C.M.; Bouwstra, J.A.; Schacht, E.H.; Junginger, H.E. In vitro evaluation of mucoadhesive properties of chitosan and some other natural polymers. Int. J. Pharm., 1992, 78, 43-48.
25. He, P.; Davis, S.S.; Illum, L. In vitro evaluation of the mucoadhesive properties of chitosan microspheres. Int. J. Pharm., 1997, 166, 75-88.
26. Bhaskara Rao, S.; Sharma, C.P. Use of chitosan as a biomaterial: Studies on its safety and hemostatic potential. J. Biomed. Mater. Res., 1997, 34, 21-28.
27. Sinha, V.R.; Singla, A.K.; Wadhawan, S.; Kaushik, R.; Kumria, R.; Bansal, K.; Dhawan, S. Chitosan microspheres as a potential carrier for drugs. Int. J. Pharm., 2004, 274, 1-33.
28. Huang, M.; Khor, E.; Lim, L.Y. Uptake and cytotoxicity of chitosan molecules and nanoparticles: effects of molecular weight and degree of deacetylation. Pharm. Res., 2004, 21, 344-353.
29. Prestwich, G.D.; Marecak, D.M.; Marecek, J.F.; Vercruysse, K.P.; Ziebell, M.R. Controlled chemical modification of hyaluronic acid: synthesis, applications, and biodegradation of hydrazide derivatives. J. Control. Release, 1998, 53, 93-103.
30. Ohya, Y.; Shiratani, M.; Kobayashi, H.; Ouchi, T. Release behaviour of 5-fluorouracil from chitosan-gel nanospheres immobilizing 5-fluorouracil coated polysaccharides and their cell specific cytotoxicity. Pure Appl. Chem. A, 1994, 31, 629-642.
31. Gan, Q.; Wang, T.; Cochrane, C.; McCarron, P. Modulation of surface charge, particle size and morphological properties of chitosan-TPP nanoparticles intended for gene delivery. Colloid Surface, B., 2005, 44, 65-73.
32. Patil, J.S.; Kamalapur, M.V.; Marapur, S.C.; Kadam, D.V. Ionotropic gelation and polyelectrolyte complexation: the novel techniques to design hydrogel particulate sustained, modulated drug delivery system: a review. Dig. J. Nanomater. Bios., 2010, 5, 241-248.
33. van de Velde, F.; De Ruiter, G.D. Carrageenan. Biopolymers Online, 2005. URL: http://dx.doi.org/10.1002/3527600035.bpol6009.
34. Tapia, C.; Escobar, Z.; Costa, E.; Sapaq-Hagar, J.; Valenzuela, F.; Basualto, C.; Gai, M.N.; Yazdani-Pedram, M. Comparative studies on polyelectrolyte complexes and mixtures of chitosan-alginate and chitosan-carrageenan as prolonged diltiazem clorhydrate release systems. Eur. J. Pharm. Biopharm., 2004, 57, 65-75.
35. Piyakulawat, P.; Praphairaksit, N.; Chantarasiri, N.; Muangsin, N. Preparation and evaluation of chitosan/carrageenan beads for controlled release of sodium diclofenac. AAPS Pharmsci., 2007, 8, 120-130.
36. Tapia, C.; Corbalan, V.; Costa, E.; Gai, M.N.; Yazdani-Pedram, M. Study of the release mechanism of diltiazem hydrochloride from matrices based on chitosan-alginate and chitosan-carrageenan mixtures. Biomacromolecules, 2005, 6, 2389-2395.
37. Devi, N.; Maji, T.K. A novel microencapsulation of neem (Azadirachta indica A. Juss.) seed oil (NSO) in polyelectrolyte complex of carrageenan and chitosan. J. Appl. Polym. Sci., 2009, 113, 1576-1583.
38. Grenha, A.; Gomes, M.E.; Rodrigues, M.; Santo, V.E.; Mano, J.F.; Neves, N.M.; Reis, R.L. Development of new chitosan/carrageenan nanoparticles for drug delivery applications. J. Biomed. Mater. Res., 2010, 92A, 1265-1272.
39. Vinogradov, S.V.; Bronich, T.K.; Kabanov, A.V. Nanosized cationic hydrogels for drug delivery: preparation, properties and interactions with cells. Adv. Drug Deliver Rev., 2002, 54, 135-147.
40. Desai, M.P.; Labhasetwar, V.; Walter, E.; Levy, R.J.; Amidon, G.L. The mechanism of uptake of biodegradable microparticles in Caco-2 cells is size dependent. Pharm. Res., 1997, 14, 1568-1573.
41. Panyam, J.; Labhasetwar, V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv. Drug Deliver. Rev., 2003, 55, 329-347.
42. Desai, M.P.; Labhasetwar, V.; Amidon, G.L.; Levy, R.J. Gastroin testinal uptake of biodegradable microparcticles: effect of particle size. Pharm. Res., 1996, 13, 1838-1845.
43. Calvo, P.; Vila-Jato, J.L.; Alonso, M.J. Effect of lysozyme on the stability of polyester nanocapsules and nanoparticles: stabilization approaches. Biomaterials., 1997, 18, 1305-1310.
44. Anderson, M.J.; Whitcomb, P.J. RSM simplified: optimizing processes using response surface methods for design of experiments; CRC Press: New York, 2005.
45. Bokharaei, M.; Margaritis, A.; Xenocostas, A.; Freeman, D.J. Erythropoietin encapsulation in chitosan nanoparticles and kinetics of drug release. Curr. Drug Del., 2011, 8, 164-171.
46. Gan, Q.; Wang, T. Chitosan nanoparticle as protein delivery carrier systematic examination of fabrication conditions for efficient loading and release. Colliod Surface B., 2007, 59, 24-34.